GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Cyclically Adjusted Revenue per Share

Regeneron Pharmaceuticals (MIC:REGN-RM) Cyclically Adjusted Revenue per Share : ₽0.00 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2025 was ₽2,250.274. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₽0.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Regeneron Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 13.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 18.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 27.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Regeneron Pharmaceuticals was 41.60% per year. The lowest was 1.40% per year. And the median was 22.40% per year.

As of today (2025-07-18), Regeneron Pharmaceuticals's current stock price is ₽0.00. Regeneron Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₽0.00. Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Regeneron Pharmaceuticals was 59.51. The lowest was 5.23. And the median was 12.95.


Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regeneron Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regeneron Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regeneron Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2250.274/134.9266*134.9266
=2,250.274

Current CPI (Mar. 2025) = 134.9266.

Regeneron Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 482.164 100.684 646.148
201509 644.622 100.392 866.375
201512 696.282 99.792 941.424
201603 711.502 100.470 955.511
201606 665.777 101.688 883.398
201609 660.839 101.861 875.357
201612 640.929 101.863 848.970
201703 641.520 102.862 841.496
201706 752.166 103.349 981.984
201709 742.332 104.136 961.826
201712 787.924 104.011 1,022.121
201803 753.174 105.290 965.179
201806 882.418 106.317 1,119.876
201809 947.169 106.507 1,199.908
201812 219.585 105.998 279.514
201903 771.374 107.251 970.428
201906 868.167 108.070 1,083.921
201909 962.813 108.329 1,199.204
201912 1,010.351 108.420 1,257.361
202003 1,264.161 108.902 1,566.268
202006 1,158.501 108.767 1,437.129
202009 1,590.395 109.815 1,954.075
202012 1,610.699 109.897 1,977.547
202103 1,736.999 111.754 2,097.165
202106 3,408.847 114.631 4,012.375
202109 2,215.124 115.734 2,582.460
202112 3,228.430 117.630 3,703.162
202203 2,752.051 121.301 3,061.186
202206 1,578.879 125.017 1,704.033
202209 1,569.539 125.227 1,691.116
202212 1,831.387 125.222 1,973.321
202303 2,087.025 127.348 2,211.229
202306 2,250.292 128.729 2,358.637
202309 2,859.333 129.860 2,970.904
202312 2,725.390 129.419 2,841.364
202403 2,500.179 131.776 2,559.951
202406 2,778.664 132.554 2,828.404
202409 2,901.794 133.029 2,943.189
202412 3,589.099 133.157 3,636.794
202503 2,250.274 134.927 2,250.274

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Regeneron Pharmaceuticals  (MIC:REGN-RM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Regeneron Pharmaceuticals was 59.51. The lowest was 5.23. And the median was 12.95.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines